Free Trial
NASDAQ:SANA

Sana Biotechnology (SANA) Stock Price, News & Analysis

Sana Biotechnology logo
$3.20 +0.28 (+9.42%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$3.19 0.00 (-0.03%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sana Biotechnology Stock (NASDAQ:SANA)

Key Stats

Today's Range
$2.94
$3.24
50-Day Range
$1.68
$3.20
52-Week Range
$1.26
$7.40
Volume
6.18 million shs
Average Volume
3.75 million shs
Market Capitalization
$720.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.17
Consensus Rating
Buy

Company Overview

Sana Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

SANA MarketRank™: 

Sana Biotechnology scored higher than 56% of companies evaluated by MarketBeat, and ranked 458th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sana Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sana Biotechnology has only been the subject of 3 research reports in the past 90 days.

  • Read more about Sana Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Sana Biotechnology are expected to grow in the coming year, from ($1.16) to ($0.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sana Biotechnology is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sana Biotechnology is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sana Biotechnology has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sana Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    34.73% of the float of Sana Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Sana Biotechnology has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Sana Biotechnology has recently decreased by 1.58%, indicating that investor sentiment is improving.
  • Dividend Yield

    Sana Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Sana Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    34.73% of the float of Sana Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Sana Biotechnology has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Sana Biotechnology has recently decreased by 1.58%, indicating that investor sentiment is improving.
  • News Sentiment

    Sana Biotechnology has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Sana Biotechnology this week, compared to 7 articles on an average week.
  • Search Interest

    Only 13 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sana Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    30.10% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sana Biotechnology's insider trading history.
Receive SANA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

SANA Stock News Headlines

Sana Biotechnology (NASDAQ:SANA) Now Covered by Morgan Stanley
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Sana Biotechnology (SANA) Receives a Buy from Citizens JMP
See More Headlines

SANA Stock Analysis - Frequently Asked Questions

Sana Biotechnology's stock was trading at $1.63 on January 1st, 2025. Since then, SANA shares have increased by 96.0% and is now trading at $3.1950.

Sana Biotechnology, Inc. (NASDAQ:SANA) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02.

Sana Biotechnology (SANA) raised $322 million in an IPO on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities served as the underwriters for the IPO.

Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sana Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

Last Earnings
5/08/2025
Today
7/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SANA
Fax
N/A
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.17
High Stock Price Target
$15.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+186.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$266.76 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.12 per share
Price / Book
2.85

Miscellaneous

Free Float
157,608,000
Market Cap
$720.41 million
Optionable
Optionable
Beta
1.86
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:SANA) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners